Horizon scanning in prostate cancer care

Oct 7, 2016
Horizon scanning in prostate cancer care

The field of oncology is experiencing a time of excitement and innovation with the development of new therapies and technologies across the board. In prostate cancer alone, huge strides are being made in clinical research away from a one-size-fits-all approach to a much more defined and targeted approach to diagnosis and treatment.

Here, Colony Brown, vice president of marketing and communications at nonprofit organization ZERO Cancer, talks through recent advances in the field, where her organization has contributed and the challenges still to be addressed.

What have been some of the most exciting advances made in prostate cancer in recent years?

The development and use of genomic tests in prostate tissue following a radical prostatectomy allows us to better understand how the disease will behave and whether the tumor is a pussy cat or a tiger. These tests also further stratify risk, providing more information on which to base treatment and disease management decisions within the physician-patient partnership.

Are there any exciting advances on the horizon for prostate cancer care?

There are several new molecules in clinical trials and other studies in place to determine the most effective sequence of treatments. In addition, there are some early detection tools in development which could have an impact in the future by helping ensure that the tumor is diagnosed at an early stage and treated based on aggressiveness of the disease. New treatment options for men who have already been diagnosed will also have potential to change cancer care.

How is ZERO involved in research to improve prostate cancer care?

Through our research fund we support ongoing clinical research at two academic medical centers –the University of California, San Francisco (UCSF), and the Oregon Health and Sciences University – one for early detection and one in advanced disease.

The UCSF research is evaluating new and improved methods for the early detection of prostate cancer, while the work at Oregon Health and Sciences University is targeting gene activation in late stage, or castration-resistant, prostate cancer.

ZERO has also been involved in psychosocial research with other organizations and leaders at academic medical centers to better understand the prostate cancer experience and improve quality of life for men living with prostate cancer. We are hopeful that through these collaborations we will secure grant funding to continue and expand these projects.

ZERO’s advocacy efforts have also ensured that the Department of Defense Prostate Cancer Research Program (PCRP) remains funded. Money from that program has directly supported researchers that helped bring the two leading anti-androgen drugs to market.

What do you think are some of the biggest issues in prostate cancer care currently?

Two areas are still in need of attention: knowledge and access. Awareness about personal risk and the value of early detection are always an issue.

When diagnosed at an early stage, prostate cancer has a very high – nearly 100 percent – five-year survival rate. However, for men diagnosed at an advanced stage that figure drops radically to less than 30 percent.1

For men that have been diagnosed early – with no metastases – it’s important to have as much information about their disease and how aggressive it is so they can make the best management plan with their physician.

For men living with advanced disease, knowing their treatment options and having access are key.


Reference

  1. Cancer.Net. Prostate Cancer – Statistics (2016). Available from: http://www.cancer.net/cancer-types/prostate-cancer/statistics (accessed September 2016).
Horizon scanning in prostate cancer care

Author

Colony Brown, ZERO Cancer’s vice president of marketing and communications has equal parts compassion and toughness, and is ZERO’s diplomat and marketing guru. Whether she’s in the front of the microphone or behind the scenes, Colony is making sure the prostate cancer cause and ZERO are front and center. Colony grew up as an Army brat living in five different places, including Germany, before starting high school in the DC area. Having an unconventional first name was her first lesson in branding and she has spent her career messaging and packaging ever since (it’s a family name, by the way). It’s no surprise that Colony has made relationship building a priority in her life. With a head for headlines and a heart for helping, she started her career at a nonprofit promoting diversity in television newsrooms. From there she joined the dotcom boom at technology startup, Cvent and then spent more than a decade marketing a top DC law firm.

Since 2013, Colony reconnected with her nonprofit roots and has made ZERO her home. Whether at CrossFit, the coffee shop, a dog park, or her favorite local Tex Mex hangout, Colony is likely to be rallying her community behind the fight to end prostate cancer. Inspired to create a future for her three kids that eliminates the pain and suffering from prostate cancer, she proudly embraces the nickname given by neighbors as the Prostate Lady. Curious how you can make prostate cancer part of your conversations? Drop her a line here or find her on Twitter at @colonybrown.

Leave a Reply